Author + information
This study investigated the role of plasma adropin levels to show endothelial dysfunction in individuals with type 2 diabetes mellitus, and to compare these with flow mediated dilatation.
A total of 92 individuals with diagnosed type 2 diabetes mellitus were included and divided into two groups, according to their brachial flow-mediated dilatation. The endothelial dysfunction group consisted of 46 participants with flow mediated dilatation change <7%, while 46 participants with flow-mediated dilatation change >7% were accepted as the non-endothelial dysfunction group. Venous blood samples were taken from all study participants, and plasma adropin levels were measured using an enzyme-linked immunosorbent assay kit.
The baseline characteristics of the patients were summarized in Table 1. The mean flow mediated dilatation values were 13.2±4.9% in Non- Endothelial Dysfunction Group and 3.5±3.4% in Endothelial Dysfunction Group. Figure 1 shows the difference of plasma adropin levels of patients between two group. The mean plasma adropin levels were found 3.04±0.79 ng/mL in ED Group and 4.67±1.43 ng/mL in Non-ED group, p<0.001. The mean HgA1C levels were significantly higher in Endothelial Dysfunction Group than Non- Endothelial Dysfunction Group (respectively, 8.7±1.9% vs 7.9±1.6%, p<0.038). Plasma adropin levels have positive weak correlation with body mass index (r=0.171, p=0.045) and they were significantly positive correlated with flow mediated dilatation values (r=0.537, p<0.001). In the linear regression analysis, adropin and HgA1C were found to be independent risk factors for endothelial dysfunction in type 2 diabetes mellitus patients (Table 2).
Adropin is a new marker for use in demonstrating endothelial dysfunction.
|Non-ED Group (n=46)||P value|
|Gender (female, %)||71.7||73.9||0.5|
Type 2 DM (mean month)
|History of (%)|
|Fasting glucose (mg/dL)||202±80||189±70||0.3|
|Total Cholesterol (mg/dL)||205±51||199±45||0.5|
|CRP (mg/L)||5.5± 5.0||4.5± 5.1||0.3|
|Waist length (cm)||111±12||108±8||0.1|
The clinical and biochemical characteristics of type 2 diabetes mellitus patients
The linear regression analysis for endothelial dysfunction in type 2 DM